These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17937779)

  • 1. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities.
    Mehdipour AR; Javidnia K; Hemmateenejad B; Amirghofran Z; Miri R
    Chem Biol Drug Des; 2007 Oct; 70(4):337-46. PubMed ID: 17937779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.
    Miri R; Mehdipour A
    Bioorg Med Chem; 2008 Sep; 16(18):8329-34. PubMed ID: 18701304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of new symmetrical derivatives of dihydropyridine containing a pyridyl group on the 3, 5-positions and evaluation of their cytotoxic and multidrug resistance reversal activity.
    Foroughinia F; Javidnia K; Amirghofran Z; Mehdipour A; Miri R
    J Pharm Pharmacol; 2008 Nov; 60(11):1481-9. PubMed ID: 18957169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
    Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
    Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
    Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
    Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line.
    Tasaki Y; Nakagawa M; Ogata J; Kiue A; Tanimura H; Kuwano M; Nomura Y
    J Urol; 1995 Sep; 154(3):1210-6. PubMed ID: 7637090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist.
    Miri R; Javidnia K; Sarkarzadeh H; Hemmateenejad B
    Bioorg Med Chem; 2006 Jul; 14(14):4842-9. PubMed ID: 16603367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines.
    Firuzi O; Javidnia K; Mansourabadi E; Saso L; Mehdipour AR; Miri R
    Arch Pharm Res; 2013 Nov; 36(11):1392-402. PubMed ID: 23674129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors.
    Sirisha K; Shekhar MC; Umasankar K; Mahendar P; Sadanandam A; Achaiah G; Reddy VM
    Bioorg Med Chem; 2011 May; 19(10):3249-54. PubMed ID: 21530277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photolabels P-glycoprotein.
    Borchers C; Ulrich WR; Klemm K; Ise W; Gekeler V; Haas S; Schödl A; Conrad J; Przybylski M; Boer R
    Mol Pharmacol; 1995 Jul; 48(1):21-9. PubMed ID: 7623771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines.
    Engi H; Sakagami H; Kawase M; Parecha A; Manvar D; Kothari H; Adlakha P; Shah A; Motohashi N; Ocsovszki I; Molnár J
    In Vivo; 2006; 20(5):637-43. PubMed ID: 17091771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyridines and multidrug resistance: previous attempts, present state, and future trends.
    Zarrin A; Mehdipour AR; Miri R
    Chem Biol Drug Des; 2010 Nov; 76(5):369-81. PubMed ID: 20925689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and 3D-QSAR study of 1,4-dihydropyridine derivatives as MDR cancer reverters.
    Radadiya A; Khedkar V; Bavishi A; Vala H; Thakrar S; Bhavsar D; Shah A; Coutinho E
    Eur J Med Chem; 2014 Mar; 74():375-87. PubMed ID: 24486418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents.
    Hosseini M; Miri R; Amini M; Mirkhani H; Hemmateenejad B; Ghodsi S; Alipour E; Shafiee A
    Arch Pharm (Weinheim); 2007 Oct; 340(10):549-56. PubMed ID: 17849444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyridines: evaluation of their current and future pharmacological applications.
    Edraki N; Mehdipour AR; Khoshneviszadeh M; Miri R
    Drug Discov Today; 2009 Nov; 14(21-22):1058-66. PubMed ID: 19729074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine).
    Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M
    Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent.
    Mollazadeh S; Shamsara J; Iman M; Hadizadeh F
    Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents.
    Khoshneviszadeh M; Edraki N; Javidnia K; Alborzi A; Pourabbas B; Mardaneh J; Miri R
    Bioorg Med Chem; 2009 Feb; 17(4):1579-86. PubMed ID: 19162489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells.
    Richter M; Molnár J; Hilgeroth A
    J Med Chem; 2006 May; 49(9):2838-40. PubMed ID: 16640345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity.
    Kawase M; Sakagami H; Motohashi N; Hauer H; Chatterjee SS; Spengler G; Vigyikanne AV; Molnár A; Molnár J
    In Vivo; 2005; 19(4):705-11. PubMed ID: 15999537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.